Boston Scientific (BSX)
NYSE:BSX
Want to see BSX full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.83Last Year’s EPS
0.75Same Quarter Last Year
Strong Buy
Based on 28 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call reflected a mixed picture: a strong Q1 with organic growth and EPS above guidance, meaningful product and regional momentum (notably in EP/PFA, WATCHMAN clinical data, Asia Pacific), and solid capital priorities (buyback, Penumbra deal). However, management lowered near-term guidance and flagged several material headwinds — weaker Urology, some EP share pressure, margin compression (gross margin down 100 bps) and operational disruptions (POLARx discontinuation and supply issues) — leading to a more cautious full-year outlook. The company emphasizes confidence in longer-term strategy and product pipeline while taking near-term actions to control costs and invest commercially.Company Guidance
Quarterly Revenue and Organic Growth Beat Guidance
Q1 consolidated revenue of $5.203B, reported growth +11.6% vs Q1 2025; operational/organic revenue growth +9.4%, above guidance range of 8.5%–10%.
Adjusted EPS and Operating Margin Performance
Q1 adjusted EPS $0.80, +6% YoY and at the high end of guidance ($0.78–$0.80); Q1 adjusted operating margin ~28.8%.
Regional Strength — U.S. and Asia Pacific
U.S. organic growth +11% with double-digit growth in five of eight business units; Asia Pacific operational growth +12%, including strong Japan and China performance.
EP / PFA Momentum and Mapping Platform Expansion
Global EP organic sales +22% (U.S. +18%, international +30%); strong uptake of FARAPULSE and OPAL mapping footprint; company expects to maintain PFA leadership and forecasts EP investment and next-generation catheter launches.
WATCHMAN Clinical Breakthrough — CHAMPION Trial
CHAMPION trial presented at ACC met primary and secondary endpoints, reinforcing WATCHMAN safety/efficacy; WATCHMAN grew +19% organically in Q1 and management expects full-year global WATCHMAN growth to be mid-teens.
Interventional Oncology and Other Business Unit Wins
Interventional Oncology organic growth +15%; Endoscopy +7% with AXIOS ramping; Cardiovascular / ICVT delivered double-digit drivers in imaging and certain therapies; regulatory approvals secured (e.g., PMDA DCB de novo, NMPA OPAL HDx).
Strong Capital Allocation and Liquidity Actions
Board approved additional $4B repurchase authorization (total $5B); intent to repurchase ~$2B in Q2; announced expected close of Penumbra acquisition in H2 2026; Q1 cash on hand $1.453B and expected full-year free cash flow ~$4B.
BSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2026 | $59.52 | $64.87 | +8.99% |
Feb 04, 2026 | $91.62 | $75.50 | -17.59% |
Oct 22, 2025 | $99.90 | $103.85 | +3.95% |
Jul 23, 2025 | $103.16 | $107.76 | +4.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Boston Scientific (BSX) report earnings?
Boston Scientific (BSX) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is Boston Scientific (BSX) earnings time?
Boston Scientific (BSX) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSX EPS forecast?
BSX EPS forecast for the fiscal quarter 2026 (Q2) is 0.83.
